Inactive Instrument

Pharmacyclics, Inc. Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

07/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

07/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
22/04/15	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
22/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
09/04/15	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
06/03/15	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
06/03/15	Wall Street closes up slightly ahead of jobs report	RE
06/03/15	AbbVie : CEO says new form of Humira could thwart generics	RE
06/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/03/15	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
02/06/14	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

08/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
08/01/16	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
08/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
08/01/16	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
08/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

06/03/15	Wall Street se reprend un peu dans un climat d'attente
06/03/15	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
05/03/15	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	01/02/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	63.48B
ARGENX SE	+1.76%	+1.27%	+11.82%	+82.12%	54.55B
LONZA GROUP AG	-0.94%	+0.99%	+10.45%	+102.18%	53.59B
IQVIA HOLDINGS INC.	+2.37%	+0.30%	+27.19%	+56.61%	44.75B
BEONE MEDICINES AG	+2.07%	-3.49%	+17.71%	+99.86%	41.62B
REVOLUTION MEDICINES, INC.	+0.93%	-3.80%	+221.30%	+918.53%	39.91B
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	32.47B
GENMAB A/S	+29.06%	+47.63%	+107.12%	+94.27%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-7.45%	+24.25%	-2.99%	23.36B
Average	+4.45%	-0.42%	+51.68%	+161.85%	42.27B
Weighted average by Cap.	+3.13%	-0.29%	+47.12%	+160.54%